In Reply Dr Altundag suggests that giving a taxane first followed by an anthracycline, as was done in the FinXX trial, might be beneficial to patients who also receive capecitabine in the adjuvant setting. In the FinXX trial, the patients were randomly allocated to either 3 cycles of docetaxel followed by 3 cycles of cyclophosphamide, epirubicin, and fluorouracil or to 3 cycles of docetaxel plus capecitabine followed by 3 cycles of cyclophosphamide, epirubicin, and capecitabine. Therefore, the patients who participated in this trial received a taxane (docetaxel) first, followed by an anthracycline (epirubicin).
from Cancer via ola Kala on Inoreader http://ift.tt/2lkoeJe
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου